Zobrazeno 1 - 10
of 80
pro vyhledávání: '"A. S. Zhabina"'
Autor:
E. V. Levchenko, F. V. Moiseenko, S. V. Orlov, E. N. Imyanitov, A. E. Mikhnin, M. L. Gelfond, E. N. Slugin, S. M. Ergnyan, N. E. Levchenko, A. S. Zhabina, A. M. Ulitin, O. Yu. Mamontov, O. O. Lopushanskaya, E. V. Artemeva, A. I. Murtazin, V. I. Shabinskaya
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 1, Pp 5-14 (2023)
Objective. To assess the overall and disease-free survival rates in patients with EGFR-mutated lung adenocarcinoma, who underwent surgery after achieving the objective response to tyrosine kinase inhibitor (TKI) therapy.Material and Methods. The over
Externí odkaz:
https://doaj.org/article/7336c9ed20724b46b7c9eb818dc1a744
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 11, Iss 3-4, Pp 11-17 (2022)
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patient
Externí odkaz:
https://doaj.org/article/2d03f1018a45430f833cbda769ac5776
Autor:
A. S. Zhabina, A. I. Novikov, F. V. Moiseenko, N. M. Volkov, E. O. Stepanova, E. V. Artemeva, N. H. Abduloeva, V. M. Moiseenko
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 8, Iss 2, Pp 34-42 (2021)
Purpose of the study. There is the generalized analysis of administration of vinflunine in real clinical practice in St.Petersburg Clinical Scientific and Practical Center of Specialized medical Care (oncological).Materials and methods. This analysis
Externí odkaz:
https://doaj.org/article/02ac5742c0f54e10b12b140e137026f4
Autor:
M. Yu. Fedyanin, F. V. Moiseenko, D. A. Chekini, V. A. Chubenko, A. S. Zhabina, L. A. Zagorskaya, M. M. Kramchaninov, S. A. Tjulandin, V. M. Moiseyenko
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 47-52 (2020)
Introduction. Trifluridine/Tipiracil (FTD/TPI) is a new chemotherapeutic drug approved in more than 60 countries for use in patients with metastatic colorectal cancer who have registered progression or intolerance to treatment with fluoropyrimidines,
Externí odkaz:
https://doaj.org/article/7960a21c1a0a4a80b8f80fc55c3111e3
Autor:
N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 165-174 (2020)
Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucir
Externí odkaz:
https://doaj.org/article/c36b27f6439d4e80b0427ab6e064acee
Autor:
N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 104-113 (2019)
Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced g
Externí odkaz:
https://doaj.org/article/585c4f001e1d4aa6b26c7d34d605422b
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 2, Pp 29-37 (2019)
Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer.Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the
Externí odkaz:
https://doaj.org/article/743bdd161bd0481991ada713bfba7dbc
Autor:
T. Y. SEMIGLAZOVA, A. S. ZHABINA, А. V. BELYAEVA, V. A. KLUGE, K. V. USOVA, D. H. LATIPOVA, G. M. TELETAEVA, A. V. NOVIK, A. I. SEMENOVA, S. A. PROTSENKO
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 56-65 (2016)
Conversion of the incurable disease in the chronic form and improvement of the life quality parameters on the background of appearance of new drugs is of specific importance for patients with NSCLC with activating mutations. “ESMO thinks that treat
Externí odkaz:
https://doaj.org/article/7ac0b7e66bad4bcaa3c872a3ba8a7d62
Autor:
Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valeriy V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Alexander E. Kuzminov, Evgeny V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergey V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Ksenia A. Sarantseva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tyurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Marina V. Chernykh, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Marina M. Khulamkhanova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 269-304 (2022)
Externí odkaz:
https://doaj.org/article/a2caace9aacc43548d9d996d4c2021f2
Autor:
Fedor V. Moiseenko, Mikhail Yu. Fedyanin, Nikita M. Volkov, Nuriniso Kh. Abduloeva, Natalya V. Levchenko, Vyacheslav A. Chubenko, Albina S. Zhabina, Maria L. Stepanova, Mikhail M. Kramchaninov, Elizaveta V. Artemeva, Vladimir M. Moiseyenko
Publikováno v:
Alʹmanah Kliničeskoj Mediciny, Vol 50, Iss 1, Pp 47-55 (2022)
Rationale: Non-small cell lung cancer (NSCLC) is an aggressive disease with median survival of 1214 months in inoperable patients in the pre-immunotherapy era. Nowadays, under treatment with checkpoint inhibitors median survival is 1922 months. Howev
Externí odkaz:
https://doaj.org/article/8287edf3421a4498985c6a66a464a8e4